Compare TLIH & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TLIH | PPCB |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | Singapore | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 18.1M |
| IPO Year | 2023 | 2011 |
| Metric | TLIH | PPCB |
|---|---|---|
| Price | $5.68 | $1.79 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.2K | ★ 160.0K |
| Earning Date | 09-30-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.06 |
| 52 Week High | $6.08 | $6.79 |
| Indicator | TLIH | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 64.42 |
| Support Level | $5.22 | $1.60 |
| Resistance Level | $5.90 | $1.98 |
| Average True Range (ATR) | 0.37 | 0.18 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 81.05 | 52.86 |
Ten-League International Holdings Ltd is a Singapore-based provider of turnkey project solutions. Its business consists of sales of heavy equipment and parts, heavy equipment rental, and provision of engineering consultancy services to port, construction, civil engineering, and underground foundation industries. It currently conducts its operations through its wholly-owned subsidiaries. The equipment it provides is organized into four categories based on their functions and application scenarios, namely, foundation equipment, hoist equipment, excavation equipment, and port machinery. The company operates in Singapore and Other international countries.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.